Table 1 Distribution of lymphomas and pertaining demographic factors in Northern Iran according to WHO classification

Total

659 (100)

389 (59)

270 (41)

1.4

50.5 ± 19.8

49.3 ± 19.6

392 (59.5)

267 (40.5)

1.4

Precursor lymphoma

B-LBL

4 (0.6)

4

0

-

48 ± 29.6

33 ± 23.5

2

2

1

T-LBL

10 (1.5)

6

4

1.5

25.1 ± 23.6

24.7 ± 23.6

9

3

3

Total

14 (2.1)

10

4

2.5

28.91 ± 24.85

27.07 ± 23.06

11

5

2.2

Hodgkin lymphoma

CHL

156 (23.7)

89

67

1.3

38.7 ± 19.6

36.5 ± 18.2

127

29

4.3

NLPHL

25 (3.8)

11

14

0.7

41.5 ± 20.2

39.3 ± 18

23

2

11.5

Total

181 (27.4)

100

81

1.2

39.13 ± 19.67

36.92 ± 18.22

150

31

4.8

B Cell lymphoma

SLL (CLL)

76 (11.5)

44

32

1.3

59.5 ± 12.6

57.8 ± 14.4

27

49

0.5

MCL

13 (2)

7

6

1.1

53.9 ± 14.1

56.7 ± 13.9

6

7

0.8

FL

20 (3)

8

12

0.6

50.9 ± 11.1

50.5 ± 10.1

9

9

1

LPL

1 (0.2)

0

1

-

46

45

1

0

-

MALTOMA

37 (5.6)

19

18

1.05

64.2 ± 14.7

61.7 ± 14.9

17

20

0.8

DLBCL

224 (34)

137

87

1.5

55.9 ± 16.6

55.7 ± 16.9

125

101

1.2

TCHLBL

3 (0.5)

3

0

-

36.3 ± 17.8

36 ± 17.3

1

2

0.5

GZ

11 (1.7)

6

5

1.2

55.7 ± 17.1

55.8 ± 15.5

13

0

-

DLBCL

(Leg)

3 (0.5)

2

1

2

50 ± 28.1

48 ± 27.2

0

3

-

EBV positive large B cell

1 (0.2)

0

1

-

50

50

1

0

-

DLBCL

(Mediastinum)

2 (0.3)

2

0

-

52 ± 33.9

50.5 ± 34.6

0

2

-

PBL

2 (0.3)

2

0

-

53

40 ± 16.9

0

2

-

BL

13 (2)

10

3

3.3

23.2 ± 20.7

22.2 ± 20.8

11

4

2.7

Total

406 (61.6)

240

166

1.4

55.63 ± 17.37

54.71 ± 17.54

202

199

1.01

T Cell lymphoma

HSTL

2 (0.3)

0

2

-

30

30

0

2

-

MF

2 (0.3)

2

0

-

38

38

0

2

-

LP

23 (3.5)

11

12

0.9

65.4 ± 11.3

62.8 ± 12.9

7

19

0.3

PTCL

26 (3.9)

21

5

4.2

52.7 ± 13.9

54.1 ± 15.5

17

9

1.8

AITCL

2 (0.3)

2

0

-

20 ± 0

20 ± 0

2

0

-

ALCL

(ALK-negative)

3 (0.5)

3

0

-

42 ± 14.1

37.3 ± 11.8

3

0

-

Total

58 (8.8)

39

19

2.0

56.27 ± 18.14

54.30 ± 16.98

29

32

0.9